Covenant Hospice Inc - Dothan 104 Rock Bridge Road, Dothan, AL, 36303 | |
(334) 794-7847 |
News Archive
Although the lungs are a common target for COVID-19's cytokine storm, so are the kidneys, making the 1 in 4 U.S. adults with diabetes resulting in diabetic kidney disease at increased risk for virus mortality.
An appetite-suppressing chemical also improves glucose tolerance and lowers insulin levels in obese and diabetic mice, researchers report in the November issue of Cell Metabolism, a publication of Cell Press.
Professor Mark McGurk speaks to News-Medical about his groundbreaking research that has led to the discovery of a world-first treatment for oral cancer.
AcelRx Pharmaceuticals, Inc. has announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab product candidate for cancer breakthrough pain control.
Young cancer survivors face unique medical and psychosocial challenges that can hinder their ability to move on mentally and socially, even years after their final treatment.
› Verified 4 days ago
Name | Covenant Hospice Inc - Dothan |
---|---|
Location | 104 Rock Bridge Road, Dothan, Alabama |
Hospice ID | 011577 |
Category | Freestanding Hospice |
Ownership Type | Proprietary - Corporation |
Profit Type | FOR PROFIT |
Accreditation Provider | The Joint Commission (TJC) |
SSA county code | 340 |
News Archive
Although the lungs are a common target for COVID-19's cytokine storm, so are the kidneys, making the 1 in 4 U.S. adults with diabetes resulting in diabetic kidney disease at increased risk for virus mortality.
An appetite-suppressing chemical also improves glucose tolerance and lowers insulin levels in obese and diabetic mice, researchers report in the November issue of Cell Metabolism, a publication of Cell Press.
Professor Mark McGurk speaks to News-Medical about his groundbreaking research that has led to the discovery of a world-first treatment for oral cancer.
AcelRx Pharmaceuticals, Inc. has announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab product candidate for cancer breakthrough pain control.
Young cancer survivors face unique medical and psychosocial challenges that can hinder their ability to move on mentally and socially, even years after their final treatment.
› Verified 4 days ago
NPI Number | 1497707962 |
Organization Name | Covenant Hospice, Inc |
Address | 104 Rock Bridge Rd Dothan, Alabama, 36303 |
Phone Number | (334)794-7847 |
News Archive
Although the lungs are a common target for COVID-19's cytokine storm, so are the kidneys, making the 1 in 4 U.S. adults with diabetes resulting in diabetic kidney disease at increased risk for virus mortality.
An appetite-suppressing chemical also improves glucose tolerance and lowers insulin levels in obese and diabetic mice, researchers report in the November issue of Cell Metabolism, a publication of Cell Press.
Professor Mark McGurk speaks to News-Medical about his groundbreaking research that has led to the discovery of a world-first treatment for oral cancer.
AcelRx Pharmaceuticals, Inc. has announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab product candidate for cancer breakthrough pain control.
Young cancer survivors face unique medical and psychosocial challenges that can hinder their ability to move on mentally and socially, even years after their final treatment.
› Verified 4 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 85.2 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 85.4 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 89.7 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 61.4 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 93.9 | 97.3 |
Patients who got timely treatment for shortness of breath | 96.2 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 96.1 | 93.3 |
News Archive
Although the lungs are a common target for COVID-19's cytokine storm, so are the kidneys, making the 1 in 4 U.S. adults with diabetes resulting in diabetic kidney disease at increased risk for virus mortality.
An appetite-suppressing chemical also improves glucose tolerance and lowers insulin levels in obese and diabetic mice, researchers report in the November issue of Cell Metabolism, a publication of Cell Press.
Professor Mark McGurk speaks to News-Medical about his groundbreaking research that has led to the discovery of a world-first treatment for oral cancer.
AcelRx Pharmaceuticals, Inc. has announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab product candidate for cancer breakthrough pain control.
Young cancer survivors face unique medical and psychosocial challenges that can hinder their ability to move on mentally and socially, even years after their final treatment.
› Verified 4 days ago
Home Health Aides | 20.7 |
Counselors | 1.4 |
Licensed Practical or Vocational Nurses | 7.3 |
Medical Social Workers | 4.2 |
Physicians | 2.6 |
Registered Nurses | 31.5 |
Other Personnel | 20.3 |
Total Employees | 88 |
---|
News Archive
Although the lungs are a common target for COVID-19's cytokine storm, so are the kidneys, making the 1 in 4 U.S. adults with diabetes resulting in diabetic kidney disease at increased risk for virus mortality.
An appetite-suppressing chemical also improves glucose tolerance and lowers insulin levels in obese and diabetic mice, researchers report in the November issue of Cell Metabolism, a publication of Cell Press.
Professor Mark McGurk speaks to News-Medical about his groundbreaking research that has led to the discovery of a world-first treatment for oral cancer.
AcelRx Pharmaceuticals, Inc. has announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab product candidate for cancer breakthrough pain control.
Young cancer survivors face unique medical and psychosocial challenges that can hinder their ability to move on mentally and socially, even years after their final treatment.
› Verified 4 days ago
Others | 174 |
Total Volunteers | 174 |
---|
News Archive
Although the lungs are a common target for COVID-19's cytokine storm, so are the kidneys, making the 1 in 4 U.S. adults with diabetes resulting in diabetic kidney disease at increased risk for virus mortality.
An appetite-suppressing chemical also improves glucose tolerance and lowers insulin levels in obese and diabetic mice, researchers report in the November issue of Cell Metabolism, a publication of Cell Press.
Professor Mark McGurk speaks to News-Medical about his groundbreaking research that has led to the discovery of a world-first treatment for oral cancer.
AcelRx Pharmaceuticals, Inc. has announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab product candidate for cancer breakthrough pain control.
Young cancer survivors face unique medical and psychosocial challenges that can hinder their ability to move on mentally and socially, even years after their final treatment.
› Verified 4 days ago
Gentiva Hospice - Dothan Location: 2740 Headland Avenue, Dothan, Alabama, 36303 Phone: (334) 794-7847 |
Covenant Hospice Inc - Dothan Location: 104 Rock Bridge Road, Dothan, Alabama, 36303 Phone: (334) 794-7847 |